comparemela.com
Home
Live Updates
Pier Franco Conte - Breaking News
Pages:
Latest Breaking News On - Pier franco conte - Page 1 : comparemela.com
ASCO 2023: Treatment De-Escalation and the Role of Age in HER2+ Breast Cancer
Studies presented at ASCO 2023 answered questions about de-escalating treatment and how age impacts outcomes in HER2+ breast cancer.
Vanderbilt university
United states
Comunidad autonoma de cataluna
Justinm balko
Javier cort
Franco conte
International breast cancer center
Vanderbilt university medical center
Veneto institute of oncology
University of padua
One year
Trastuzumab remains
Pier franco conte
Veneto institute
Identifying patients who can forgo
One Year of Adjuvant Trastuzumab Remains Standard in HER2+ Early Breast Cancer
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
Franco conte
Veneto institute of oncology
University of padua
Pier franco conte
Veneto institute
One Year of Adjuvant Trastuzumab Remains Standard in HER2+ Early Breast Cancer
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
Franco conte
Veneto institute of oncology
University of padua
Pier franco conte
Veneto institute
vimarsana © 2020. All Rights Reserved.